NASDAQ:CALA Calithera Biosciences Q3 2022 Earnings Results & Report $0.0001 0.00 (0.00%) As of 10/28/2026 11:11 AM Eastern Calithera Biosciences missed analyst earnings expectations in its Q3 2022 results, released November 14, 2022. The company reported EPS of -$2.01 versus the -$1.99 consensus estimate. Research:Profile Earnings Announcement Details QuarterQ3 2022Report DateNovember 14, 2022 Calithera Biosciences EPS ResultsActual EPS-$2.01Consensus EPS -$1.99Beat/MissMissed by -$0.02One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersCalithera Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsCalithera Biosciences' next earnings date is estimated for Tuesday, November 17, 2026, based on past reporting schedules. Conference Call ResourcesCompany Profile Calithera Biosciences Q3 2022 Earnings FAQ Did Calithera Biosciences beat earnings estimates for Q3 2022? Calithera Biosciences (NASDAQ:CALA) reported earnings of -$2.01 per share for Q3 2022, missing the consensus estimate of -$1.99. The report was announced on Monday, November 14, 2022. When is Calithera Biosciences' next earnings date? Calithera Biosciences' next earnings date is estimated for Tuesday, November 17, 2026. MarketBeat tracks confirmed and estimated earnings dates for Calithera Biosciences on the company's earnings history page. Calithera Biosciences Earnings HeadlinesCalithera Biosciences (NASDAQ:CALA) Stock Breaks Above 50 Day Moving Average - Here's What HappenedOctober 20, 2026 | americanbankingnews.comCalithera Biosciences Inc (CALA)November 23, 2024 | investing.comBuffett's Final Warning: "The Dollar Is Going to Hell"In 2025, the dollar lost 12% in value. Real inflation hit 5%+. 12% + 5% = 17% purchasing power gone. And it's happening again this year. And next year. And the year after that. The people who understand this are already moving. In a free presentation I just recorded, I'm revealing what we call "The 2026 AI Gold Rush." The ONE AI-linked asset class the U.S. government has no choice but to fuel… and BlackRock, Goldman Sachs, and 170 public companies are already positioning into it. The same strategy that delivered 12,480% for Mastercard investors since its 2006 IPO. Sitting idle isn't "playing it safe." It's the most expensive decision you'll make this decade.October 29 at 1:00 AM | Decentralized Masters (Ad)Christina CalaAugust 12, 2023 | npr.orgNCalithera Biosciences cancels special meeting due to lack of quorumJune 29, 2023 | seekingalpha.comCALA - Calithera Biosciences, Inc.May 31, 2023 | finance.yahoo.comSee More Calithera Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Calithera Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Calithera Biosciences and other key companies, straight to your email. Email Address About Calithera BiosciencesCalithera Biosciences (NASDAQ:CALA) was a clinical-stage biotechnology company focused on developing small-molecule therapies that target cancer metabolism. The company’s research centered on metabolic pathways that tumors use to support growth and survival, with the goal of improving outcomes for patients with cancer. Its lead investigational product was telaglenastat (CB-839), an oral inhibitor of glutaminase, an enzyme involved in glutamine metabolism. Calithera evaluated telaglenastat in combination with other treatments for cancers including renal cell carcinoma, triple-negative breast cancer and hematologic malignancies. The company also developed CB-280, an investigational arginase inhibitor intended for potential use in solid tumors. Founded in 2010 and based in South San Francisco, California, Calithera conducted clinical-development activities primarily in the United States, with research and collaborations involving international pharmaceutical companies. Susan Molineaux, a co-founder, served as the company’s president and chief executive officer for much of its operating history. Calithera later discontinued development activities and ceased operating as an active biotechnology company.View Calithera Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Where's the Beef? Trian-Led Buyout Proposal Values Wendy's at $1.4B, But Is It Enough?Alphabet’s Cloud Is Paying Off—But the Bill for Building It Keeps GrowingPlugging In: Vertiv Cashes In On AI DemandGE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.Phillips 66 Posts Strong Earnings But the Stock Doesn't CareConstellation Energy's Nuclear Expansion Gets a $5 Billion Opening, Not a GuaranteeVisa's Toll Booth Keeps Collecting, But the Price Is Rising Upcoming Earnings Colgate-Palmolive (10/30/2026)BP (10/30/2026)Chevron (10/30/2026)ExxonMobil (10/30/2026)NatWest Group (10/30/2026)AbbVie (10/30/2026)AstraZeneca (10/30/2026)Regeneron Pharmaceuticals (10/30/2026)Sanofi (10/30/2026)Canadian National Railway (10/30/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
